"Eli Lilly’s investigational drug retatrutide has demonstrated unprecedented weight loss of up to 23.4% in adults with type 2 diabetes and obesity, alongside substantial improvements in glycemic control, as confirmed by peer-reviewed data published in The Lancet."
This groundbreaking finding from the TRIUMPH-2 trial offers a beacon of hope for individuals grappling with the dual challenges of type 2 diabetes and obesity, conditions that often exacerbate each other. The full results, now rigorously vetted and published, reveal that the highest dose of retatrutide, a novel triple agonist, achieved an average weight loss of 60.8 pounds over 80 weeks in a specific subgroup of participants. This marks a significant advancement in the therapeutic landscape, potentially reshaping treatment paradigms for millions worldwide.
The TRIUMPH-2 Phase 3 clinical trial, a pivotal study funded by Eli Lilly, the pharmaceutical giant behind retatrutide, enrolled 1,152 adults diagnosed with type 2 diabetes and either obesity or overweight. Participants were randomly assigned to receive weekly subcutaneous injections of retatrutide at three different dosages—4 mg, 9 mg, or 12 mg—or a placebo. The study’s baseline characteristics painted a clear picture of the patient population: an average starting weight of 234.6 pounds, a body mass index (BMI) of 38.2, and an average hemoglobin A1C (HbA1c) level of approximately 7.7%. These metrics underscore the significant metabolic challenges faced by the trial participants, highlighting the need for potent therapeutic interventions.
The efficacy estimand analysis, a metric favored by Eli Lilly, showcased a dose-dependent response in weight reduction. At the 80-week mark, participants receiving the 4 mg dose experienced an average weight loss of 12.7%, while those on the 9 mg dose achieved 19.1% weight reduction. The most striking results emerged from the 12 mg dose group, where patients shed an average of 20.8% of their body weight. In comparison, the placebo group saw a more modest 4.0% weight loss.
However, a more conservative analysis, which accounted for all participants regardless of whether they completed the full treatment course, yielded slightly lower but still impressive figures. This approach, designed to reflect real-world adherence challenges, reported average weight losses of 11.9% for the 4 mg dose, 16.8% for the 9 mg dose, and 18.8% for the 12 mg dose, compared to 5.1% for the placebo. Crucially, a subgroup analysis focusing on individuals with a BMI of 35 or higher revealed even more substantial weight loss, reaching an average of 23.4% of body weight at the highest dose. This specific finding is particularly relevant as it targets a population with a more severe degree of obesity, often associated with greater health risks.
Beyond weight management, retatrutide demonstrated significant benefits in glycemic control. HbA1c levels, a key indicator of long-term blood sugar management, saw substantial reductions across all retatrutide treatment arms. The average HbA1c fell by 1.4, 1.6, and 1.5 percentage points for the 4 mg, 9 mg, and 12 mg doses, respectively, a marked improvement compared to the 0.2 percentage point reduction observed in the placebo group. Notably, up to 40% of participants receiving retatrutide achieved an HbA1c level below 5.7%, the threshold for normal, non-diabetic blood sugar levels. Furthermore, at the highest dose, an impressive 59.5% of participants no longer met the BMI criteria for obesity, signifying a profound impact on their overall health status.
The metabolic benefits extended to other cardiovascular risk factors. At the 12 mg dose, retatrutide treatment led to a 39.5% decrease in triglyceride levels, a 19.6% reduction in non-high-density lipoprotein (non-HDL) cholesterol, and a 10.8 mmHg drop in systolic blood pressure. A significant 58.3% reduction in high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation, was also observed. While these improvements are highly encouraging and suggest a potential for reduced cardiovascular morbidity, it is crucial to note that the TRIUMPH-2 trial was not specifically designed to demonstrate a reduction in heart attacks or strokes.
The pharmacological mechanism behind retatrutide’s potent effects lies in its unique action as a triple agonist. Eli Lilly has engineered this single molecule to activate receptors for three key hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This multi-pronged approach distinguishes it from existing therapies. Semaglutide, marketed as Ozempic for diabetes and Wegovy for weight loss, targets the GLP-1 receptor. Tirzepatide, available as Mounjaro for diabetes and Zepbound for weight loss, activates both GLP-1 and GIP receptors. By incorporating the glucagon pathway, retatrutide introduces an additional mechanism that primarily influences liver function and the body’s energy expenditure, potentially contributing to its superior weight-loss efficacy.
However, this enhanced efficacy comes with a commensurate profile of gastrointestinal side effects, which are common among incretin-based therapies. Diarrhea affected a significant proportion of participants, ranging from 27.4% to 33.6% in the retatrutide groups compared to 13.2% in the placebo group. Nausea was reported by up to 28.0% of retatrutide users, versus 8.0% on placebo, and vomiting occurred in up to 15.7% compared to 4.2%. A less common but notable side effect was dysesthesia, an abnormal or uncomfortable skin sensation, which occurred in 4.5% to 7.3% of retatrutide recipients, compared to 0.7% in the placebo arm.
These side effects can have a tangible impact on daily life, affecting appetite, digestion, and overall comfort, which can disrupt work, meals, and sleep for individuals and their families. Consequently, treatment discontinuation due to adverse events was observed more frequently in the retatrutide groups, reaching 11.6% at the 9 mg dose and 7.7% at the 12 mg dose, compared to 4.9% for the placebo.
Despite the challenges, the magnitude of weight loss achieved by retatrutide has garnered significant attention from the medical community. Dr. Juan P. Frías, Medical Director and Principal Investigator at the Los Angeles Institute for Metabolic Research, commented in an Eli Lilly release that "Results such as these may change what we set out to achieve with a single therapy for adults living with type 2 diabetes and obesity."
Independent experts echoed this sentiment, albeit with a more measured perspective. Philip Newland-Jones from the University of Southampton highlighted the historical difficulty in achieving substantial weight loss in individuals with diabetes, stating that "making the average of almost 21% weight loss with retatrutide especially impressive." Helen O’Neil, a senior medicines optimization pharmacist, noted that while the side effects appear comparable to other incretin-based therapies, "head-to-head studies are needed to determine its place in treatment pathways."
The publication of the full TRIUMPH-2 results in The Lancet follows earlier reporting of topline figures by MedicalDaily prior to the European Association for the Study of Diabetes meeting in Milan on September 28, 2026. The peer-reviewed publication provides a more comprehensive analysis, including the specific subgroup data for individuals with a BMI of 35 or higher, the conservative treatment-regimen numbers, and a more detailed side-effect profile.
Crucially, retatrutide is not yet approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body. Eli Lilly has indicated plans to submit an application to the FDA in the first quarter of 2027. Regulatory review typically takes several months, meaning that retatrutide is unlikely to be available by prescription outside of clinical trials until mid-2027 at the earliest. Key details such as pricing, insurance coverage, and direct comparative efficacy against existing treatments like tirzepatide and semaglutide remain unknown.
This availability gap presents a significant concern, as unapproved products marketed as retatrutide have already surfaced on the market, appearing at medical spas and online retailers. These products are not the rigorously tested drug used in the TRIUMPH-2 trial, and their contents, dosage accuracy, and sterility cannot be guaranteed. Consumers seeking these unverified substances risk significant health consequences.
For individuals with type 2 diabetes and obesity who are interested in the potential benefits of retatrutide, the recommended course of action is to discuss these findings with their healthcare provider. Clinicians can assess individual health histories, current medications, and insurance plans to determine if currently approved treatment options, such as tirzepatide or semaglutide, are appropriate. It is critical to emphasize that patients should never alter or discontinue their prescribed diabetes medications without consulting a healthcare professional, as abrupt changes can severely impact blood sugar control.
Individuals who may have already obtained or are using injectable products marketed as retatrutide should immediately inform their physician. Prompt medical attention is warranted for severe abdominal pain, persistent vomiting, signs of dehydration, or dangerously low blood sugar levels.
The peer-reviewed confirmation of substantial weight and blood sugar improvements with retatrutide in a Lilly-funded trial, particularly in individuals with a higher baseline BMI, represents a significant advancement. However, the immediate focus for patients should remain on established, approved therapies. The upcoming FDA review process, anticipated after early 2027, will be a critical determinant of retatrutide’s future role in clinical practice. Until then, informed discussions with healthcare providers about existing treatment options are the most prudent step.
